iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011. In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $200million of proceeds.
This additional capital will allow us to continue to develop our clinical pipeline and maintain our investments in our discovery research team to leverage its fantastic science to improve the lives of cancer patients. For more information, please visit www.iteostherapeutics.com.
The Global Head of Translational Medicine is responsible for Translational Medicine and Clinical Pharmacology across all programs in iTeos. The scope includes both small molecules and monoclonal antibodies and covers activities from late stage preclinical through to Ph III trials. Key objectives are to make the translational medicine process and activities within the company as efficient as possible and to get trials up and running quickly, getting on top of the emerging stream of data and translating it from data to information, ensuring that the company continues to do cutting-edge work, and supporting the earlier stage trials.
iTeos is committed to a broad and deep translational medicine effort with emphasis in understanding the mechanism of action of drugs to maximize the potential of drug candidates for patients. The company has a strong focus on the identification and validation of biomarkers which can be used across both discovery and development to predict and confirm target binding, determine mechanism of action, and to monitor disease status, stratify patients, and determine treatment efficacy in clinical trials.
Fundamental to the role is the ability to craft and execute biomarker strategies for each program, ideally for the development of predictive biomarkers but also to build understanding of the mechanism of action of iTeos drugs. Collaborative interactions with research scientists, clinicians, toxicologists, pharmacokineticists, modeling and simulation experts, clinical trial managers, data managers, biostatisticians and regulatory affairs will be critical to success in the role. The appointee will be an experienced translational medicine leader who would like to leverage their experience to drive the success of a dynamic entrepreneurial company. They will be committed to scientific excellence with expertise in cutting edge techniques in immune oncology drug development.
The Global Head of Translational Medicine will lead a department comprising around 14 FTEs (Director to Research Assistant level) based in Gosselies, Belgium. This department is set to expand by another 5 FTEs over the coming months. The team comprises laboratory-based staff involved in the identification and development of assays to support biomarker activities. These assays are subsequently transferred to CROs for validation and routine executions. Immuno-histochemistry and exploratory work around mechanism of action are also delivered by this team. The role reports to the VP R&D, also based in Belgium, with a close working relationship to the CMO, based in Cambridge, MA (US).
iTeos is seeking a collaborative, dynamic and enthusiastic individual who is a proven leader with a demonstrable track record of strategic planning and execution. The appointee is experienced in scenario planning, negotiating with CROs, and has overseen data management and medical writing. The appointee will attend executive committee and Board meetings when applicable and will be required to present at them as necessary. iTeos is a collaborative, matrixed organization and the placed candidate will be adept at working alongside colleagues in other functional areas in a collegial manner. The appointee will assume management of a small team and will be expected to attract and onboard additional support as needed. The existing team is a group of dedicated scientists, committed to excellence. Cultural fit and attention to professional development are essential characteristics of the appointee.
This is an opportunity to work with a small collegial team that is dedicated to bringing novel medicines to patients. The appointee will take ownership of translational medicine in a company with solid funding and the resources to advance the clinical pipeline rapidly.
Please send your CV together with an adapted cover letter to the following address : email@example.com. Please, mention the reference GH-TM in the mail object. Your application and related information will remain strictly confidential.
For our recruitments in Belgium and USA, we closely collaborate with a Recruitment & Selection company, Coulter Partners. Your application will be automatically forwarded to them. We, together with Coulter Partners, will keep all your data confidential (GDPR compliant approach)